Arrowhead Pharmaceuticals, Inc. Common Stock ARWR
HEALTHCARE · BIOTECHNOLOGYi
Market dataready · fetched 2026-11-07T07:26:29.654Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-06T21:00:02.230470504Z
FundamentalsAlpha Vantage · ready · quarter 2026-06-30 · fetched 2026-11-07T07:26:29.076820+00:00
Arrowhead Pharmaceuticals, Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 68.31 | 88.9% | 19.3% | 52.08 | 76.3% | 12.2% |
| 25Δ | 64.77 | 75.6% | 13.4% | 53.25 | 79.0% | 10.9% |
| 30Δ | 63.74 | 79.9% | 12.3% | 54.36 | 81.6% | 9.8% |
| 35Δ | 62.70 | 84.3% | 11.3% | 55.49 | 82.8% | 8.6% |
| 40Δ | 61.33 | 80.7% | 9.4% | 56.65 | 81.9% | 7.5% |
| 45Δ | 59.90 | 75.4% | 7.4% | 57.75 | 79.7% | 6.3% |
| 50Δ | 58.85 | 73.8% | 6.3% | 58.68 | 73.8% | 5.1% |
| 55Δ | 57.80 | 72.1% | 5.2% | 59.61 | 68.0% | 4.0% |
| 60Δ | 56.83 | 70.4% | 4.3% | 60.83 | 69.6% | 3.3% |
| 65Δ | 55.89 | 68.6% | 3.5% | 62.26 | 76.5% | 3.0% |
| 70Δ | 54.93 | 67.1% | 2.7% | 63.94 | 81.2% | 2.5% |
| 75Δ | 53.61 | 70.7% | 2.3% | 66.31 | 89.8% | 2.2% |
| 80Δ | 52.24 | 74.3% | 1.8% | 68.37 | 91.3% | 1.7% |
20Δ
- Pseudo strike
- 68.31
- IV
- 88.9%
- B/E move
- 19.3%
- Pseudo strike
- 52.08
- IV
- 76.3%
- B/E move
- 12.2%
25Δ
- Pseudo strike
- 64.77
- IV
- 75.6%
- B/E move
- 13.4%
- Pseudo strike
- 53.25
- IV
- 79.0%
- B/E move
- 10.9%
30Δ
- Pseudo strike
- 63.74
- IV
- 79.9%
- B/E move
- 12.3%
- Pseudo strike
- 54.36
- IV
- 81.6%
- B/E move
- 9.8%
35Δ
- Pseudo strike
- 62.70
- IV
- 84.3%
- B/E move
- 11.3%
- Pseudo strike
- 55.49
- IV
- 82.8%
- B/E move
- 8.6%
40Δ
- Pseudo strike
- 61.33
- IV
- 80.7%
- B/E move
- 9.4%
- Pseudo strike
- 56.65
- IV
- 81.9%
- B/E move
- 7.5%
45Δ
- Pseudo strike
- 59.90
- IV
- 75.4%
- B/E move
- 7.4%
- Pseudo strike
- 57.75
- IV
- 79.7%
- B/E move
- 6.3%
50Δ
- Pseudo strike
- 58.85
- IV
- 73.8%
- B/E move
- 6.3%
- Pseudo strike
- 58.68
- IV
- 73.8%
- B/E move
- 5.1%
55Δ
- Pseudo strike
- 57.80
- IV
- 72.1%
- B/E move
- 5.2%
- Pseudo strike
- 59.61
- IV
- 68.0%
- B/E move
- 4.0%
60Δ
- Pseudo strike
- 56.83
- IV
- 70.4%
- B/E move
- 4.3%
- Pseudo strike
- 60.83
- IV
- 69.6%
- B/E move
- 3.3%
65Δ
- Pseudo strike
- 55.89
- IV
- 68.6%
- B/E move
- 3.5%
- Pseudo strike
- 62.26
- IV
- 76.5%
- B/E move
- 3.0%
70Δ
- Pseudo strike
- 54.93
- IV
- 67.1%
- B/E move
- 2.7%
- Pseudo strike
- 63.94
- IV
- 81.2%
- B/E move
- 2.5%
75Δ
- Pseudo strike
- 53.61
- IV
- 70.7%
- B/E move
- 2.3%
- Pseudo strike
- 66.31
- IV
- 89.8%
- B/E move
- 2.2%
80Δ
- Pseudo strike
- 52.24
- IV
- 74.3%
- B/E move
- 1.8%
- Pseudo strike
- 68.37
- IV
- 91.3%
- B/E move
- 1.7%
Options history
Table
| Date | IV (%) |
|---|---|
| 53.16% | |
| 54.90% | |
| 53.49% | |
| 55.24% | |
| 52.73% | |
| 54.10% | |
| 55.61% | |
| 56.39% | |
| 54.89% | |
| 53.90% |
Biotechnology
ASMB
Assembly Biosciences, Inc. is a clinical-stage biotechnology company in the United States. The company is headquartered in South San Francisco, California.
More →ASND
Ascendis Pharma A / S, a biopharmaceutical company, develops therapies for unmet medical needs. The company is headquartered in Hellerup, Denmark.
More →ATNM
Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplantation (BMT) or a type of…
More →ATOS
Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops drugs in the areas of oncology and infectious diseases. The company is headquartered…
More →AUPH
Aurinia Pharmaceuticals Inc., a biopharmaceutical company, develops and markets therapies to treat various diseases with unmet medical needs in Japan and China. The company is…
More →AURA
Aura Biosciences Inc is a pioneering clinical-stage biotechnology company focused on transforming cancer treatment through its unique virus-like particle (VLP) technology. The…
More →